 Stockopedia |
Sandoz Negotiates Expanded RoW Rights to Vectura's Asthma/COPD Drug VR315
Genetic Engineering News The Novartis generics business, Sandoz, negotiated expanded, rest-of-world (excluding the US) rights to Vectura's VR315 candidate combination therapy for asthma/COPD. Sandoz already holds European rights to the dry powder inhaler product. … Vectura Extends Novartis Deal For VR315 Lung Drug VECTURA GROUP PLC : VR315 RoW License Agreement Vectura signs up Sandoz for asthma drug in RoW; good results for ALK Abello … |
View full post on asthma – Google News